Levioxap (Nitrous Oxide, Oxygen)

Nitrous oxide produces its effects by antagonizing N‑methyl‑D‑aspartate (NMDA) receptors in the central nervous system and by enhancing endogenous opioid pathways. This dual action depresses neuronal activity, reduces pain transmission, and induces a state of conscious sedation, allowing patients to remain responsive while experiencing diminished discomfort.

The specific concentration and flow rate of nitrous oxide/oxygen administered with Levioxap are determined by the prescribing clinician based on the patient’s age, weight, procedure type, and clinical response. Dosage is titrated to achieve the desired level of sedation while maintaining adequate oxygenation and safety parameters.

Safety data for nitrous oxide/oxygen use during pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies the potential risk to the fetus. Use while breastfeeding is generally avoided unless clinically necessary.

To place an order, submit an enquiry on the Levioxap product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Levioxap’s nitrous oxide‑oxygen mixture offers rapid onset, easy titration, and a favorable safety profile compared with volatile anesthetic agents that require airway instrumentation. Unlike pure oxygen, it provides analgesia, and unlike opioid analgesics, it does not cause respiratory depression when used at appropriate concentrations, making it suitable for brief procedures.

Levioxap should be stored at ambient temperature, in a well‑ventilated, dry area away from direct sunlight and heat sources. Cylinders must be secured upright, protected from impact, and kept in their original packaging until use. Ensure that the gas delivery system is checked for leaks before each use and that appropriate scavenging equipment is available.

Levioxap is delivered via a calibrated inhalation system, typically a face mask or nasal hood, allowing the patient to inhale a controlled mixture of nitrous oxide and oxygen. The clinician adjusts the gas flow to achieve the desired level of sedation while continuously monitoring oxygen saturation, respiratory rate, and hemodynamic parameters throughout the procedure.

The most serious risks include hypoxia due to inadequate oxygen delivery, severe respiratory depression, loss of consciousness, and cardiovascular instability such as hypotension or arrhythmias. Rarely, prolonged exposure can lead to vitamin B12 deficiency or neurotoxicity. Prompt recognition and immediate cessation of the gas, along with supportive measures, are essential to mitigate these risks.

Levioxap is contraindicated in patients with known hypersensitivity to nitrous oxide or oxygen, severe chronic obstructive pulmonary disease, untreated pneumothorax, or those who cannot maintain a patent airway. It should also be avoided in individuals with increased intracranial pressure, certain psychiatric conditions, or in settings lacking appropriate monitoring and scavenging equipment.